Dec 18 (Reuters) - Sarepta Therapeutics Inc SRPT.O:
SAREPTA THERAPEUTICS COMPLETES ENROLLMENT IN EMERGENE, A PHASE 3 CLINICAL STUDY OF SRP-9003 FOR THE TREATMENT OF LIMB-GIRDLE MUSCULAR DYSTROPHY TYPE 2E/R4
ANTICIPATES FILING FOR ACCELERATED APPROVAL OF SRP-9003 IN 2025
Source text: ID:nBw355zxra
Further company coverage: SRPT.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.